Scar Prevention Clinical Trial
Official title:
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF EXC 001 FOR THE AMELIORATION OF SCARRING OF THE SURGICAL INCISION IN SUBJECTS UNDERGOING AN ELECTIVE ABDOMINOPLASTY
This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty. The study will also evaluate the safety of EXC 001 in healthy adult subjects.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00892723 -
A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars
|
Phase 2 | |
Active, not recruiting |
NCT06312527 -
Mepiform in Simultaneous Bilateral TKA
|
N/A | |
Completed |
NCT00825916 -
A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars
|
Phase 2 | |
Completed |
NCT01640912 -
Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109
|
Phase 1 | |
Completed |
NCT04707131 -
A Study of Single Ascending Dose of LEM-S401 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT04722705 -
Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention
|
N/A | |
Terminated |
NCT01826942 -
Scar Prevention Using Fractional Carbon Dioxide Laser Treatment
|
N/A | |
Completed |
NCT00811577 -
A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients
|
Phase 2 | |
Completed |
NCT01037413 -
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery
|
Phase 2 | |
Completed |
NCT01780077 -
Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109
|
Phase 1 | |
Completed |
NCT01038297 -
Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
|
Phase 2 |